EULAR 2008 - Rheumatoid Arthritis : Anti-B-Cell Therapy
The Annual European Congress of Rheumatology was held in Paris, France from June 11-14, 2008. This is the official meeting of the European League Against Rheumatism (EULAR). Full abstract reports may be can be found online by visiting the EULAR Congress website. While it is not possible to review all of the important findings from these meetings, some selected highlights are summarized. These highlights focus on Rheumatoid Arthritis. The highlights are summarized by Joan Bathon, M.D. and Jon Giles, M.D.
- OP-0123 The Effects of Repeated Doses of Briobacept (BR3-FC) in Patients with Rheumatoid Arthritis
- OP-0134 Combination Rituximab and Leflunomide Produces Lasting Responses in Rheumatoid Arthritis
- OP-0250 The Safety and Efficacy of Ocrelizumab; a Humanized anti-CD20 Antibody Administered as a Single Infusion Regimen to Patients with Active Rheumatoid Arthritis
- OP-0252 Repeated Therapy with TRU-015 is Well Tolerated and Results in Consistent Pharmacodynamic Effects in Rheumatoid Arthritis Patients
- OP-0253 A Single Course of Rituximab does not Abrogate Anti-Infliximab Antibodies in Patients with Rheumatoid Arthritis
